Stock listing

SIX Swiss:SANN Santhera Pharmaceuticals Holding AG Aktie

Home listing (SIX Swiss) of Santhera Pharmaceuticals Holding AG

Follow Santhera Pharmaceuticals Holding AG into a list and get an email when it puts out news.

Share price · SIX:SANN

14.42 CHF 0.00 (0.0%)

Close on Oct 19, 2026

Since Jul 6, 2026 -2.7% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
14.00 – 14.46 CHFOct 19, 2026
Volume
33,669 sharesOct 19, 2026
Market value
220.9M CHFAt the close on Oct 19, 2026 · price × 15.32M shares outstanding
Santhera Pharmaceuticals Holding AG logo
Ticker
SIX Swiss:SANN
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
SIX Swiss
Currency
CHF

What changed lately

Calls

Replays

  • Santhera Pharmaceuticals Holding (SIX Swiss: SANN) Q2 2026 Earnings Call

    Wed, Sep 30, 2026 · 8:00 AM ET

    Watch Transcript

  • Santhera Pharmaceuticals Holding (SIX Swiss: SANN) Q4 2025 Earnings Call

    Tue, Apr 28, 2026 · 8:00 AM ET

    Watch Transcript

  • Santhera Pharmaceuticals Holding (SIX Swiss: SANN) Q2 2025 Earnings Call

    Tue, Sep 23, 2025 · 8:00 AM ET

    Watch Transcript

Latest news

Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

Jul 13, 2026

Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

Jun 2, 2026

Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

Apr 30, 2026

Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy

Apr 28, 2026

Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

Apr 28, 2026

Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU

Apr 27, 2026

Santhera Appoints Orlando Oliveira as Chief Executive Officer

Apr 23, 2026

Full Year 2025 Trading Update

Mar 12, 2026

Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth

Mar 10, 2026

AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy

Mar 9, 2026

All Santhera Pharmaceuticals Holding AG news

Decks

Santhera Pharmaceuticals Holding AG on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
17 in the last 12 months · 33 in all · newest Jul 13, 2026 · oldest 2025
Calls
4 calls with a replay · 4 with a transcript · latest Sep 30, 2026
Decks
11 decks · latest Sep 30, 2026

Where Santhera Pharmaceuticals Holding AG is listed

ListingExchangeCountryCurrency
SIX Swiss:SANN · Home listing · This pageSIX SwissSwitzerlandCHF
OTC:SPHDFOTCUnited StatesUSD
LSE:0QN1LSEUnited KingdomCHF
gettex:S3F0gettexGermanyEUR
LS Exchange:A3EJMQLS ExchangeGermanyEUR
Lang & Schwarz:A3EJMQLang & SchwarzGermanyEUR
Aquis:SANNZAquisUnited KingdomCHF
BX Swiss:S3F0BX SwissSwitzerlandCHF
Tradegate:S3F0TradegateGermanyEUR
Dusseldorf:S3F0DusseldorfGermanyEUR
Frankfurt:S3F0FrankfurtGermanyEUR
Hamburg:S3F0HamburgGermanyEUR
Munich:S3F0MunichGermanyEUR
Stuttgart:S3F0StuttgartGermanyEUR
Turquoise:SANNZTurquoiseUnited KingdomCHF

Log in to ask 6ix AI your own questions about Santhera Pharmaceuticals Holding AG.